ES2811554T3 - Uso de inhibidores de CCR3 - Google Patents
Uso de inhibidores de CCR3 Download PDFInfo
- Publication number
- ES2811554T3 ES2811554T3 ES13713199T ES13713199T ES2811554T3 ES 2811554 T3 ES2811554 T3 ES 2811554T3 ES 13713199 T ES13713199 T ES 13713199T ES 13713199 T ES13713199 T ES 13713199T ES 2811554 T3 ES2811554 T3 ES 2811554T3
- Authority
- ES
- Spain
- Prior art keywords
- eosinophilic
- chloride
- alkyl
- compound
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Immunology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Structure Of Transmissions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12162937 | 2012-04-03 | ||
| PCT/EP2013/056864 WO2013149986A1 (en) | 2012-04-03 | 2013-04-02 | Use of ccr3-inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2811554T3 true ES2811554T3 (es) | 2021-03-12 |
Family
ID=48040249
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13713199T Active ES2811554T3 (es) | 2012-04-03 | 2013-04-02 | Uso de inhibidores de CCR3 |
| ES20174399T Active ES2987267T3 (es) | 2012-04-03 | 2013-04-02 | Uso de inhibidores de CCR3 para tratar degeneración macular seca relacionada con la edad |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES20174399T Active ES2987267T3 (es) | 2012-04-03 | 2013-04-02 | Uso de inhibidores de CCR3 para tratar degeneración macular seca relacionada con la edad |
Country Status (28)
| Country | Link |
|---|---|
| US (5) | US20130261153A1 (OSRAM) |
| EP (3) | EP2833884B1 (OSRAM) |
| JP (2) | JP2015512432A (OSRAM) |
| KR (5) | KR20200044988A (OSRAM) |
| CN (2) | CN110384699A (OSRAM) |
| AU (1) | AU2013245027B2 (OSRAM) |
| BR (1) | BR112014023795B1 (OSRAM) |
| CA (1) | CA2869269C (OSRAM) |
| CL (1) | CL2014002523A1 (OSRAM) |
| CY (1) | CY1123222T1 (OSRAM) |
| DK (1) | DK2833884T3 (OSRAM) |
| EA (1) | EA032263B1 (OSRAM) |
| ES (2) | ES2811554T3 (OSRAM) |
| HR (1) | HRP20201165T1 (OSRAM) |
| HU (1) | HUE051648T2 (OSRAM) |
| IL (1) | IL234262A (OSRAM) |
| IN (1) | IN2014DN06989A (OSRAM) |
| LT (1) | LT2833884T (OSRAM) |
| MX (1) | MX2014011786A (OSRAM) |
| NZ (1) | NZ628882A (OSRAM) |
| PH (1) | PH12014502239A1 (OSRAM) |
| PL (1) | PL2833884T3 (OSRAM) |
| PT (1) | PT2833884T (OSRAM) |
| RS (1) | RS60665B1 (OSRAM) |
| SI (1) | SI2833884T1 (OSRAM) |
| SM (1) | SMT202000499T1 (OSRAM) |
| WO (1) | WO2013149986A1 (OSRAM) |
| ZA (1) | ZA201406082B (OSRAM) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8278302B2 (en) | 2009-04-08 | 2012-10-02 | Boehringer Ingelheim International Gmbh | Substituted piperidines as CCR3 antagonists |
| UA109290C2 (uk) | 2010-10-07 | 2015-08-10 | Спільні кристали і солі інгібіторів ccr3 | |
| US8680280B2 (en) | 2012-04-02 | 2014-03-25 | Boehringer Ingelheim International Gmbh | Process for the manufacturing of CRR inhibitors |
| US20130261153A1 (en) * | 2012-04-03 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Use of ccr3-inhibitors |
| US10213421B2 (en) | 2012-04-04 | 2019-02-26 | Alkahest, Inc. | Pharmaceutical formulations comprising CCR3 antagonists |
| WO2018097209A1 (ja) | 2016-11-24 | 2018-05-31 | キリシマ精工株式会社 | 歯列矯正具、および歯列矯正具の取付方法 |
| BR112019020798A2 (pt) * | 2017-04-05 | 2020-04-28 | Alkahest Inc | métodos e composições para tratamento de danos associados ao envelhecimento usando inibidores de ccr3 |
| JP7179755B2 (ja) * | 2017-04-05 | 2022-11-29 | アルカヘスト インコーポレイテッド | Ｃｃｒ３阻害剤を使用した網膜関連疾患を治療するための方法および組成物 |
| KR20200067859A (ko) * | 2017-10-13 | 2020-06-12 | 알카헤스트 인코포레이티드 | Ccr3-억제제를 사용한 소양증, 건조증, 및 관련 질환을 치료하기 위한 방법 및 조성물 |
| US11426399B2 (en) | 2018-05-15 | 2022-08-30 | Alkahest, Inc. | Treatment of aging-associated disease with modulators of leukotriene A4 hydrolase |
| WO2020069008A1 (en) * | 2018-09-26 | 2020-04-02 | Alkahest, Inc. | Methods and compositions for treating aging-associated impairments using ccr3-inhibitors |
| AU2021287906B2 (en) * | 2020-06-11 | 2025-09-11 | Alkahest Inc. | Methods of improving retina-associated disease outcome using CCR3-inhibitors |
| US11957671B2 (en) | 2021-11-01 | 2024-04-16 | Alkahest, Inc. | Benzodioxane modulators of leukotriene A4 hydrolase (LTA4H) for prevention and treatment of aging-associated diseases |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6339087B1 (en) * | 1997-08-18 | 2002-01-15 | Syntex (U.S.A.) Llc | Cyclic amine derivatives-CCR-3 receptor antagonists |
| JP5198704B2 (ja) * | 2000-03-03 | 2013-05-15 | メディミューン リミティド | エオタキシンに対するヒト抗体及びそれらの使用 |
| US20020151064A1 (en) * | 2001-02-07 | 2002-10-17 | Children's Hospital Medical Center | Regulation of CCR3 expression |
| US8030003B2 (en) * | 2004-12-07 | 2011-10-04 | Children's Hospital Medical Center | Diagnosis of eosinophilic esophagitis based on presence of an elevated level of eotaxin-3 |
| US8008092B2 (en) * | 2007-10-09 | 2011-08-30 | University Of Kentucky Research Foundation | CCR3 inhibition for ocular angiogenesis and macular degeneration |
| WO2010069979A1 (en) * | 2008-12-16 | 2010-06-24 | Nycomed Gmbh | Pyran derivatives as ccr3 modulators |
| EP2236520A1 (en) * | 2009-03-31 | 2010-10-06 | Leukocare Ag | Stabilizing composition for immobilized biomolecules |
| US8278302B2 (en) * | 2009-04-08 | 2012-10-02 | Boehringer Ingelheim International Gmbh | Substituted piperidines as CCR3 antagonists |
| US8778616B2 (en) * | 2009-05-26 | 2014-07-15 | University Of Kentucky Research Foundation | Method of using CCR3 binding agents to detect choroidal neovascularization |
| UA109290C2 (uk) * | 2010-10-07 | 2015-08-10 | Спільні кристали і солі інгібіторів ccr3 | |
| US20130261153A1 (en) * | 2012-04-03 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Use of ccr3-inhibitors |
| US10213421B2 (en) * | 2012-04-04 | 2019-02-26 | Alkahest, Inc. | Pharmaceutical formulations comprising CCR3 antagonists |
| WO2020115836A1 (ja) * | 2018-12-05 | 2020-06-11 | 東浜工業株式会社 | ブロワー装置 |
-
2013
- 2013-03-27 US US13/851,564 patent/US20130261153A1/en not_active Abandoned
- 2013-04-02 EA EA201401083A patent/EA032263B1/ru unknown
- 2013-04-02 NZ NZ628882A patent/NZ628882A/en unknown
- 2013-04-02 SM SM20200499T patent/SMT202000499T1/it unknown
- 2013-04-02 KR KR1020207011392A patent/KR20200044988A/ko not_active Ceased
- 2013-04-02 KR KR1020147027679A patent/KR20140144200A/ko not_active Ceased
- 2013-04-02 KR KR1020227031439A patent/KR20220132012A/ko not_active Ceased
- 2013-04-02 WO PCT/EP2013/056864 patent/WO2013149986A1/en not_active Ceased
- 2013-04-02 JP JP2015503847A patent/JP2015512432A/ja active Pending
- 2013-04-02 SI SI201331753T patent/SI2833884T1/sl unknown
- 2013-04-02 RS RS20200868A patent/RS60665B1/sr unknown
- 2013-04-02 CA CA2869269A patent/CA2869269C/en active Active
- 2013-04-02 KR KR1020257028220A patent/KR20250133980A/ko active Pending
- 2013-04-02 HR HRP20201165TT patent/HRP20201165T1/hr unknown
- 2013-04-02 LT LTEP13713199.1T patent/LT2833884T/lt unknown
- 2013-04-02 IN IN6989DEN2014 patent/IN2014DN06989A/en unknown
- 2013-04-02 ES ES13713199T patent/ES2811554T3/es active Active
- 2013-04-02 EP EP13713199.1A patent/EP2833884B1/en active Active
- 2013-04-02 EP EP20174399.4A patent/EP3763369B1/en active Active
- 2013-04-02 DK DK13713199.1T patent/DK2833884T3/da active
- 2013-04-02 BR BR112014023795-6A patent/BR112014023795B1/pt active IP Right Grant
- 2013-04-02 PL PL13713199T patent/PL2833884T3/pl unknown
- 2013-04-02 CN CN201910406245.7A patent/CN110384699A/zh active Pending
- 2013-04-02 EP EP24158785.6A patent/EP4389217A3/en active Pending
- 2013-04-02 HU HUE13713199A patent/HUE051648T2/hu unknown
- 2013-04-02 AU AU2013245027A patent/AU2013245027B2/en active Active
- 2013-04-02 PT PT137131991T patent/PT2833884T/pt unknown
- 2013-04-02 CN CN201380016333.7A patent/CN104220073A/zh active Pending
- 2013-04-02 MX MX2014011786A patent/MX2014011786A/es unknown
- 2013-04-02 KR KR1020217015686A patent/KR20210063481A/ko not_active Ceased
- 2013-04-02 ES ES20174399T patent/ES2987267T3/es active Active
-
2014
- 2014-08-19 ZA ZA2014/06082A patent/ZA201406082B/en unknown
- 2014-08-24 IL IL234262A patent/IL234262A/en active IP Right Grant
- 2014-09-24 CL CL2014002523A patent/CL2014002523A1/es unknown
- 2014-10-03 PH PH12014502239A patent/PH12014502239A1/en unknown
- 2014-12-15 US US14/570,298 patent/US20150099783A1/en not_active Abandoned
-
2015
- 2015-11-30 US US14/953,480 patent/US20160081998A1/en not_active Abandoned
-
2017
- 2017-07-25 US US15/658,918 patent/US20170319567A1/en not_active Abandoned
- 2017-12-22 JP JP2017246173A patent/JP2018080183A/ja not_active Withdrawn
-
2020
- 2020-07-23 CY CY20201100678T patent/CY1123222T1/el unknown
- 2020-08-19 US US16/997,772 patent/US20200375971A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2811554T3 (es) | Uso de inhibidores de CCR3 | |
| ES2370751T3 (es) | Agente profiláctico o terapéutico para la degeneración macular asociada a la edad. | |
| ES3044310T3 (en) | Pharmaceutical formulations comprising ccr3 antagonists | |
| RU2406499C2 (ru) | Профилактическое или терапевтическое средство для лечения кератоконъюнктивитных нарушений | |
| JPS63185927A (ja) | 薬物中毒治療のための医薬 | |
| ES2950453T3 (es) | Compuestos y composiciones farmacéuticas para su uso en el tratamiento de enfermedades asociadas a la retina utilizando inhibidores de la CCR3 | |
| CN111432814B (zh) | 用于减轻或治疗包括脆性X染色体综合征、Angelman综合征或Rett综合征的发育障碍的氨基甲酸酯化合物的用途 | |
| HK40015701A (en) | Use of ccr3-inhibitors | |
| JP2010111667A (ja) | フェキソフェナジン又はエバスチンを含有する鎮咳及び／又は去痰のための医薬組成物 | |
| WO2016006621A1 (ja) | Ｐｇｄ２拮抗剤を含有するアレルギー性疾患に伴う症状の治療用医薬 | |
| US20240335395A1 (en) | Compositions and methods for preventing and/or treating disease associated with il-23 expression | |
| KR102739607B1 (ko) | 카바메이트 화합물을 포함하는 조현병의 예방, 경감 또는 치료용 배합물 | |
| CN105497021A (zh) | 胺类化合物治疗焦虑障碍的医药用途 | |
| WO2007066678A1 (ja) | 角結膜障害治療剤 | |
| JP2010111666A (ja) | セチリジンを含有する鎮咳及び／又は去痰のための医薬組成物 |